PDF(Pubmed)
Abstract：
Diabetes mellitus is a prevalent disorder with multi-system manifestations, causing a significant burden in terms of disability and deaths globally. Angio-tensin receptor-neprilysin inhibitor (ARNI) belongs to a class of medications for treating heart failure, with the benefits of reducing hospitalization rates and mortality. This review mainly focuses on the clinical and basic investigations related to ARNI and diabetic complications, discussing possible physiological and molecular mechanisms, with insights for future applications.
摘要：
糖尿病是一种多系统表现的常见病,在全球范围内造成严重的残疾和死亡负担。血管紧张素受体脑啡肽抑制剂（ARNI）属于一类治疗心力衰竭的药物，具有降低住院率和死亡率的益处。这篇综述主要集中在与ARNI和糖尿病并发症相关的临床和基础研究。讨论可能的生理和分子机制，对未来应用的见解。
